Last updated on May 2020

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent Resectable Osteosarcoma

Brief description of study

The purpose of this study is to evaluate the safety and efficacy of nivolumab, or nivolumab in combination with azacitidine in participants with recurrent, resectable osteosarcoma

Detailed Study Description

Treatment will be administered in 28 day cycles with the first cycle in the neoadjuvant setting. This will be followed by surgery to render the participant in surgical remission. Subsequently the participant will continue to receive treatment for up to 12 additional cycles or until recurrence, whichever occurs first. For participants with known bilateral lung recurrence, the nodule[s] in one lung should be resected, prior to the first cycle of chemotherapy.

Clinical Study Identifier: NCT03628209

Find a site near you

Start Over

Phoenix Children's Hospital

Phoenix, AZ United States
  Connect »

Nemours Children's Hospital

Jacksonville, FL United States
  Connect »

Nemours Children's Clinic

Orlando, FL United States
  Connect »

Johns Hopkins All Children's Hospital

Saint Petersburg, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.